IL233217B - Anti-human papillomavirus compounds - Google Patents
Anti-human papillomavirus compoundsInfo
- Publication number
- IL233217B IL233217B IL233217A IL23321714A IL233217B IL 233217 B IL233217 B IL 233217B IL 233217 A IL233217 A IL 233217A IL 23321714 A IL23321714 A IL 23321714A IL 233217 B IL233217 B IL 233217B
- Authority
- IL
- Israel
- Prior art keywords
- vaccines against
- against hpv
- hpv
- vaccines
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161578542P | 2011-12-21 | 2011-12-21 | |
| PCT/EP2012/076404 WO2013092875A1 (en) | 2011-12-21 | 2012-12-20 | Vaccines against hpv |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL233217A0 IL233217A0 (en) | 2014-08-31 |
| IL233217B true IL233217B (en) | 2019-05-30 |
Family
ID=47471832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL233217A IL233217B (en) | 2011-12-21 | 2014-06-18 | Anti-human papillomavirus compounds |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9901635B2 (enExample) |
| EP (2) | EP2793937B1 (enExample) |
| JP (1) | JP6258864B2 (enExample) |
| KR (1) | KR102057265B1 (enExample) |
| CN (1) | CN104039833B (enExample) |
| AU (1) | AU2012356969B2 (enExample) |
| BR (1) | BR112014015016B1 (enExample) |
| CA (1) | CA2858963C (enExample) |
| DK (1) | DK2793937T3 (enExample) |
| ES (1) | ES2730718T3 (enExample) |
| HU (1) | HUE043361T2 (enExample) |
| IL (1) | IL233217B (enExample) |
| PT (1) | PT2793937T (enExample) |
| RU (1) | RU2644201C2 (enExample) |
| TR (1) | TR201908199T4 (enExample) |
| WO (1) | WO2013092875A1 (enExample) |
| ZA (1) | ZA201404516B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014140176A1 (en) * | 2013-03-15 | 2014-09-18 | Vaccibody As | Targeting vaccines for veterinary use |
| US10286058B2 (en) * | 2014-01-13 | 2019-05-14 | Baylor Research Institute | Vaccines against HPV and HPV-related diseases |
| BR112017002809A2 (pt) * | 2014-08-15 | 2017-12-19 | Genexine Inc | métodos para tratar câncer cervical |
| SG10202001501QA (en) * | 2015-08-20 | 2020-04-29 | Janssen Vaccines & Prevention Bv | Therapeutic hpv18 vaccines |
| KR102833333B1 (ko) | 2016-01-08 | 2025-07-11 | 니코데 테라퓨틱스 에이에스에이 | 치료적 항암 네오에피토프 백신 |
| US12005112B2 (en) | 2017-09-07 | 2024-06-11 | University Of Oslo | Vaccine molecules |
| US12268736B2 (en) | 2017-09-07 | 2025-04-08 | University Of Oslo | Vaccine molecules |
| IL297049A (en) | 2020-04-09 | 2022-12-01 | Nykode Therapeutics ASA | Individualized therapeutic anticancer vaccine |
| PH12022552820A1 (en) | 2020-04-24 | 2024-03-25 | Genexine Inc | Method for treating cervical cancer |
| EP4143210A1 (en) | 2020-05-01 | 2023-03-08 | Nykode Therapeutics ASA | Betacoronavirus prophylaxis and therapy |
| US20240173391A1 (en) | 2021-03-26 | 2024-05-30 | Nykode Therapeutics ASA | Therapeutic combination for treating cancer |
| US20250339509A1 (en) | 2021-05-03 | 2025-11-06 | Nykode Therapeutics ASA | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases |
| EP4337247A1 (en) | 2021-05-10 | 2024-03-20 | Nykode Therapeutics ASA | Tolerance-inducing constructs and compositions and their use for the treatment of immune disorders |
| JP2024518463A (ja) | 2021-05-10 | 2024-05-01 | ナイコード セラピューティクス アルメン アクスイェ セルスカプ | 構築物及び免疫阻害化合物の共発現 |
| WO2022238402A1 (en) | 2021-05-10 | 2022-11-17 | Nykode Therapeutics ASA | Tolerance-inducing constructs and composition and their use for the treatment of immune disorders |
| WO2022238381A2 (en) | 2021-05-10 | 2022-11-17 | Nykode Therapeutics ASA | Immunotherapy constructs for treatment of disease |
| BR112023023260A2 (pt) | 2021-05-10 | 2024-01-30 | Nykode Therapeutics ASA | Vetor, métodos para produzir um vetor e para tratar um sujeito tendo uma doença ou uma doença infecciosa, célula hospedeira, e, composição farmacêutica |
| WO2022238363A1 (en) | 2021-05-10 | 2022-11-17 | Nykode Therapeutics ASA | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases |
| AU2022381515A1 (en) | 2021-11-03 | 2024-05-09 | Adaptive Biotechnologies Corporation | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2 |
| WO2024092025A1 (en) | 2022-10-25 | 2024-05-02 | Nykode Therapeutics ASA | Constructs and their use |
| WO2024100196A1 (en) | 2022-11-09 | 2024-05-16 | Nykode Therapeutics ASA | Co-expression of constructs and polypeptides |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9105383D0 (en) | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| AUPN015794A0 (en) | 1994-12-20 | 1995-01-19 | Csl Limited | Variants of human papilloma virus antigens |
| EP1553966B1 (en) | 2002-10-03 | 2012-08-01 | Wyeth Holdings Corporation | Fusion peptides comprising the human papillomavirus e7 and e6 polypeptides and immunogenic compositions thereof |
| EP2862878B1 (en) * | 2003-02-25 | 2022-11-02 | Nykode Therapeutics ASA | Modified antibody |
| PL1576967T3 (pl) * | 2004-03-18 | 2008-03-31 | Pasteur Institut | Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne |
| WO2006081323A2 (en) | 2005-01-26 | 2006-08-03 | The Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin |
| WO2011161244A1 (en) * | 2010-06-25 | 2011-12-29 | Vaccibody As | Homodimeric protein constructs |
-
2012
- 2012-12-20 AU AU2012356969A patent/AU2012356969B2/en active Active
- 2012-12-20 HU HUE12809271A patent/HUE043361T2/hu unknown
- 2012-12-20 CN CN201280064089.7A patent/CN104039833B/zh active Active
- 2012-12-20 TR TR2019/08199T patent/TR201908199T4/tr unknown
- 2012-12-20 KR KR1020147020468A patent/KR102057265B1/ko active Active
- 2012-12-20 WO PCT/EP2012/076404 patent/WO2013092875A1/en not_active Ceased
- 2012-12-20 EP EP12809271.5A patent/EP2793937B1/en active Active
- 2012-12-20 EP EP19166523.1A patent/EP3533462A1/en not_active Withdrawn
- 2012-12-20 JP JP2014548019A patent/JP6258864B2/ja active Active
- 2012-12-20 ES ES12809271T patent/ES2730718T3/es active Active
- 2012-12-20 US US14/365,536 patent/US9901635B2/en active Active
- 2012-12-20 CA CA2858963A patent/CA2858963C/en active Active
- 2012-12-20 BR BR112014015016-8A patent/BR112014015016B1/pt active IP Right Grant
- 2012-12-20 PT PT12809271T patent/PT2793937T/pt unknown
- 2012-12-20 RU RU2014129788A patent/RU2644201C2/ru active
- 2012-12-20 DK DK12809271.5T patent/DK2793937T3/da active
-
2014
- 2014-06-18 IL IL233217A patent/IL233217B/en active IP Right Grant
- 2014-06-19 ZA ZA2014/04516A patent/ZA201404516B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TR201908199T4 (tr) | 2019-06-21 |
| CN104039833B (zh) | 2018-01-30 |
| PT2793937T (pt) | 2019-06-05 |
| BR112014015016A8 (pt) | 2023-05-09 |
| WO2013092875A1 (en) | 2013-06-27 |
| AU2012356969B2 (en) | 2017-05-04 |
| EP2793937B1 (en) | 2019-04-10 |
| JP2015508284A (ja) | 2015-03-19 |
| RU2644201C2 (ru) | 2018-02-08 |
| ZA201404516B (en) | 2017-04-26 |
| KR20140107569A (ko) | 2014-09-04 |
| HUE043361T2 (hu) | 2019-08-28 |
| ES2730718T3 (es) | 2019-11-12 |
| EP3533462A1 (en) | 2019-09-04 |
| NZ626124A (en) | 2016-07-29 |
| US20150056197A1 (en) | 2015-02-26 |
| CN104039833A (zh) | 2014-09-10 |
| RU2014129788A (ru) | 2016-02-10 |
| US20150306217A9 (en) | 2015-10-29 |
| HK1202442A1 (en) | 2015-10-02 |
| CA2858963A1 (en) | 2013-06-27 |
| DK2793937T3 (da) | 2019-07-01 |
| US9901635B2 (en) | 2018-02-27 |
| EP2793937A1 (en) | 2014-10-29 |
| AU2012356969A1 (en) | 2014-07-03 |
| IL233217A0 (en) | 2014-08-31 |
| KR102057265B1 (ko) | 2019-12-18 |
| JP6258864B2 (ja) | 2018-01-10 |
| BR112014015016A2 (pt) | 2020-10-27 |
| BR112014015016B1 (pt) | 2023-10-03 |
| CA2858963C (en) | 2023-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201404516B (en) | Vaccines against hpv | |
| IL235890A0 (en) | vaccine | |
| GB201005005D0 (en) | New vaccine | |
| GB201223386D0 (en) | Vaccine | |
| IL231132A0 (en) | Viral cleaning methods | |
| IL231043A (en) | vaccine | |
| GB201119999D0 (en) | Vaccine | |
| GB201014965D0 (en) | Vaccine | |
| ZA201306245B (en) | Combination vaccines | |
| PT2686011T (pt) | Vacina contra npi | |
| ZA201404512B (en) | Malaria vaccine | |
| GB201013006D0 (en) | Vaccine | |
| GB201006324D0 (en) | Vaccine | |
| GB201120000D0 (en) | Vaccine | |
| GB201210226D0 (en) | Vaccine | |
| GB201202090D0 (en) | Vaccine | |
| ZA201302154B (en) | Vaccine | |
| GB201108984D0 (en) | Vaccines | |
| GB201108982D0 (en) | Vaccines | |
| GB201108986D0 (en) | Vaccines | |
| GB201121647D0 (en) | Vaccine | |
| GB201108256D0 (en) | Vaccine | |
| GB201109294D0 (en) | Novel vaccine | |
| AU2011900262A0 (en) | Combination vaccines | |
| GB201008795D0 (en) | Vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |